This past June, the U.S. Food and Drug Administration approved Aduhelm (aducanumab) for the treatment of Alzheimer’s disease via an Accelerated Approval pathway. Accelerated Approvals are intended as temporary approvals that require further proof that a new drug has meaningful benefits for patients. Since then, there have been many discussions and reviews by scientists, physicians, and healthcare providers.
If you would like to learn more, we recommend the following statement from the National Institute on Aging (NIA), the leading federal institution for Alzheimer’s Research. NIA is a funding agency of the ACAD study.